Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib in pediatric Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase
2025-522138-29-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 2, open-label, single-arm trial of asciminib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Major Molecular Response at Week 48. Planned start Jun 2026; status: authorised.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2025-522138-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522138-29-00.